载脂蛋白AI与动脉粥样硬化治疗新进展
摘要
血中载脂蛋白AⅠ（ApoAⅠ）浓度与动脉粥样硬化的发生率呈负相关。ApoAⅠ是体内抗动脉粥样硬化的因素，是预测冠心病发病危险的指标之一。在意大利乡村的一些居民体内发现了ApoAⅠ Milano，这些人高密度脂蛋白胆固醇水平极低，但却很少发生心血管病。从而在ApoAⅠ Milano对动脉粥样硬化的临床治疗方面进行了一系列研究。近期已研制出此类相关实验性药物：ECT-216，可以清除动脉粥样硬化斑块。这是第一次一种药物能显著地逆转动脉粥样硬化。本文就ApoAⅠ与动脉粥样硬化治疗新进展综述如下。
出处
《中国医药导刊》
2005年第5期331-332,共2页
Chinese Journal of Medicinal Guide
参考文献21
-
1Deng YB,Wang XF, Li CL. A new noninvasive method for evaluation of coronary endothelial function in hypertensive patients based on change in diameter of the left main coronary artery induced by cold pressor test using echocardiography[J] . Clin Cardiol, 2001; 24:291 ～ 296.
-
2Deng YB, Wang DW, Li CL, et al. Effects of the angiotensin receptor antagonist losartan on the response of the left main coronary artery to cold pressor test in patients with essential hypertension as assessed by eehocardiography [J] .Can J Cardiol, 2002; 18: 389～ 396.
-
3陈立伟,蔺洁.高胆固醇血症和炎症共同作用导致动脉粥样硬化形成[J].中国动脉硬化杂志,2004,12(3):253-253. 被引量：6
-
4Bogaty P, Poirier P,Simard S, et al. Biological profiles in subjects with recurrent acute coronary events compared with subjects with longstanding stable angina. Circulation, 2001; 103(25): 3062 ～ 3068.
-
5Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high - density lipoprotein cholesterol: Veterans Affairs High - Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med, 1999;341:410～ 418.
-
6Kazi D, Farmer JA. Raising high - density lipoprotein cholesterol:innovative strategies against an old adversary. Curr Atheroscler Rep,2005;7(2) :88 ～ 94.
-
7Toth PP. Revese Cholesterol tronsport: HDL'S magnificent mile. Curr Atherescler Rep, 2003; 31: 386.
-
8邹阳春,胡大一,杨新春,贾兴元,王乐丰,刘晓惠,魏妤,高明明,顼志敏,崔亮.国人载脂蛋白A1基因多态性与血脂水平及冠心病的关系[J].中国动脉硬化杂志,2003,11(4):345-348. 被引量：21
-
9Van Lenten BJ, Wagner AC, Nayak DP, et al. High - density lipoprotein loses its anti - inflammatory properties during acute influenza A infection. Circulation,2001; 103:2283 ～ 2288.
-
10Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA - I Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. JAMA, 2003;290: 2292～ 2300.
二级参考文献19
-
1Vega GL,Grundy SM.Hypoalphalipoprteinemia as risk factor for coronoary heart disease.Curr Opin Lipidol,1996,7:209-216
-
2Sylvie B, Cynthia RC, Tracey AMN, Darren MH. Effect of acylglyceride content on the structure and function of reconstituted high density lipoprotein particles.J lipid Res,2001,42:79-87
-
3Oscar PM, Eric B, Guide F, Nathalie D, Brigitte L, Jean-Paul B, et al. Metabolism of apolipoproteins A1 and A1I in subjects carrying similar ApoA1, mutations, ApoA1 Milano and ApoA1 Paris. Atherosclerosis, 2001, 148:317-326.
-
4Mirian L,Patrizia u, Daniela G,Alberico LC,Pettri TK.Identification of domsins in ApoA1 susceptible to proteolysis by mast cell chymase:implications for HDL function.J Lipid Res,2000,41:975-984
-
5Luc G, Bard JM, Evans A, Arveiler D, Ruidavets JB, Amouyel P, et al. The relationship between apolipoprotein A-I-containing lipoprotein fiactions and environmental facuas: the prospective epidemiological study of myocardial infarction(PRIME study).Atherosclerosis, 2000, 152:399-405.
-
6Lahoz C,Schaefer FJ,Cupples LA,Wilson PWF,Levy D,Osgood D,et al.Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study.Atherosclerosis,2001,154:529-537
-
7Kuhlencordt PJ,Chen J,Han F,Astem J,Huang PL.Genetic deficiency of inducible niteic oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice.Circulation.2001,103:3 099-104
-
8Barre DE,Guerra R,Verstraete R,Wang X,Grundy SM,Cohen JC.Genetic analysis of a polymorphism in the human apolipoprotein A1 gene promoter,effect on plasma HDL-cholesterol levels.J Lipid Res,1994,35:1 292-296
-
9Wang XL, Badenhop R,Humphrey K,Wilcken EDL.New MspI polymorphism at the +83bp of the human apolipoprotein A1 gene:association with increased circulating high density lipoprotein.Genet Epidem,1996,13:1-10
-
10Miller M,Aiello D,Prithard H,Friel G,Zeller K.Apolipoprotein A1 zavalla (Leu159-pro),HDl cholesterol deficiency in a kindred associated with premature coronary artery disease.Arterioscler Thromb Vasc Biol,1998,18:1 242-247
共引文献25
-
1陈龙,赵倩,汪美霞.桃红四物汤加味治疗VA-TIA的临床疗效及对机体同型半胱氨酸与载脂蛋白A1水平的影响[J].世界最新医学信息文摘,2020(60):165-166.
-
2吴琼.动脉粥样硬化患者餐后血脂异常管理[J].吉林医药学院学报,2010,31(5):293-296. 被引量：1
-
3黄克钧,朱中玉,高传玉,张嘉莹,陈岩,牛振民.脂蛋白(a)及其联合其他血脂指标对冠心病诊断价值的评价[J].中国动脉硬化杂志,2004,12(5):589-592. 被引量：13
-
4殷治华,杨秀兰.动脉粥样硬化的发病机制假说——炎症学说[J].山西医药杂志,2006,35(4):322-324. 被引量：13
-
5王延坤,赵斐,张勇,刘艳环,姜宁,张薇.载脂蛋白AⅠ基因多态性与老年人群血脂水平关系的研究[J].中国老年学杂志,2006,26(5):577-580. 被引量：2
-
6邹阳春,胡大一,洪秀芳,杨新春,贾兴元.载脂蛋白E基因多态性与老年冠心病患者发病的相关性研究[J].中华老年多器官疾病杂志,2006,5(1):56-57.
-
7张雄信,徐力辛.脂质代谢相关基因多态性与冠心病[J].中国分子心脏病学杂志,2006,6(6):350-354.
-
8王洪娟,李震中.载脂蛋白A1／C3／A4／A5基因簇多态性研究进展[J].国际脑血管病杂志,2007,15(8):615-620.
-
9汪晓燕,牛晓红,陈卫衡,林娜,宋剑南,陈冰,金红.载脂蛋白A1、B基因多态性对非创伤性股骨头坏死发生的影响[J].中国骨伤,2008,21(2):99-102. 被引量：12
-
10王强,马东明,张瑞峰.银杏叶提取物EGB761对高胆固醇血症家兔动脉粥样硬化的防治作用[J].江西中医学院学报,2009,21(6):45-47. 被引量：1
-
1闫吉霞,张学军,何平,王学惠.β受体阻滞剂对高血压病人血脂水平影响的研究[J].河南实用神经疾病杂志,2003,6(2):55-56. 被引量：1
-
2抗生素可能增加乳腺癌发病危险[J].河南医学研究,2004,13(1):96-96.
-
3青霉素可能对卒中有预防作用[J].河南医学研究,2003,12(4):380-380.
-
4他汀类药物能降低结直肠癌发病危险[J].中国处方药,2005(6):49-49.
-
5孕期补充维生素C增加子代哮喘危险[J].中国农村医学杂志,2005,3(3):26-26.
-
6张建荣.依那普利与卡托普利治疗原发性高血压疗效比较[J].中国临床药学杂志,2006,15(3):191-191. 被引量：1
-
7麻黄素能增加中风和心脏病的危险[J].新疆医药保健,2002(08S):55-55.
-
8王蔼明.用不用雌激素要看年龄[J].中国医药指南,2008,6(12):76-77.
-
9叶平.以高密度脂蛋白为靶标的抗动脉粥样硬化治疗策略[J].中华心血管病杂志,2008,36(9):784-785. 被引量：5
-
10方丽.小儿支气管炎发病危险因素分析及其护理策略研究[J].临床医药文献电子杂志,2017,4(5):896-897. 被引量：6
